1. Home
  2. MAIA vs CGTX Comparison

MAIA vs CGTX Comparison

Compare MAIA & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MAIA
  • CGTX
  • Stock Information
  • Founded
  • MAIA 2018
  • CGTX 2007
  • Country
  • MAIA United States
  • CGTX United States
  • Employees
  • MAIA N/A
  • CGTX N/A
  • Industry
  • MAIA Biotechnology: Pharmaceutical Preparations
  • CGTX Biotechnology: Pharmaceutical Preparations
  • Sector
  • MAIA Health Care
  • CGTX Health Care
  • Exchange
  • MAIA Nasdaq
  • CGTX Nasdaq
  • Market Cap
  • MAIA 62.4M
  • CGTX 79.3M
  • IPO Year
  • MAIA 2022
  • CGTX 2021
  • Fundamental
  • Price
  • MAIA $2.82
  • CGTX $0.55
  • Analyst Decision
  • MAIA
  • CGTX Buy
  • Analyst Count
  • MAIA 0
  • CGTX 6
  • Target Price
  • MAIA N/A
  • CGTX $8.00
  • AVG Volume (30 Days)
  • MAIA 60.0K
  • CGTX 588.8K
  • Earning Date
  • MAIA 11-05-2024
  • CGTX 11-08-2024
  • Dividend Yield
  • MAIA N/A
  • CGTX N/A
  • EPS Growth
  • MAIA N/A
  • CGTX N/A
  • EPS
  • MAIA N/A
  • CGTX N/A
  • Revenue
  • MAIA N/A
  • CGTX N/A
  • Revenue This Year
  • MAIA N/A
  • CGTX N/A
  • Revenue Next Year
  • MAIA N/A
  • CGTX N/A
  • P/E Ratio
  • MAIA N/A
  • CGTX N/A
  • Revenue Growth
  • MAIA N/A
  • CGTX N/A
  • 52 Week Low
  • MAIA $0.82
  • CGTX $0.34
  • 52 Week High
  • MAIA $5.99
  • CGTX $2.95
  • Technical
  • Relative Strength Index (RSI)
  • MAIA 50.98
  • CGTX 54.28
  • Support Level
  • MAIA $2.36
  • CGTX $0.50
  • Resistance Level
  • MAIA $2.72
  • CGTX $0.64
  • Average True Range (ATR)
  • MAIA 0.22
  • CGTX 0.07
  • MACD
  • MAIA 0.02
  • CGTX 0.02
  • Stochastic Oscillator
  • MAIA 72.28
  • CGTX 67.74

About MAIA MAIA Biotechnology Inc.

MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company. The company develops targeted immunotherapies for cancer. The company is an immune-oncology company, focused on the development of first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. The company's program is THIO, a potential cancer telomere-targeting agent in clinical development for the treatment of telomerase-positive cancer cells.

About CGTX Cognition Therapeutics Inc.

Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.

Share on Social Networks: